<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="662">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05152537</url>
  </required_header>
  <id_info>
    <org_study_id>AHNTU-CML-001</org_study_id>
    <nct_id>NCT05152537</nct_id>
  </id_info>
  <brief_title>FLOR3 Gene Polymorphism in Predicting Outcomes of Tyrosine Kinase Inhibitor（TKI）Stopping in Chronic Myeloid Leukemia</brief_title>
  <acronym>NTU-CML-001</acronym>
  <official_title>A Multicenter Prospective Cohort Study of FLOR3 Gene Polymorphism in Predicting Outcomes of TKI-stopping in Chronic Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affiliated Hospital of Nantong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Affiliated Hospital of Nantong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For patients with chronic myeloid leukemia in chronic phase (CML-CP) who have achieved a&#xD;
      stable deep molecular response (DMR) using BCR-ABL1 tyrosine kinase inhibitors (TKIs),&#xD;
      treatment-free remission (TFR) following TKI cessation is an emerging goal. However, about&#xD;
      half of the patients relapsed after TKI discontinuation. There is no definite examinations to&#xD;
      predict the outcome of TKI discontinuation. We aim to study the relationship between FLOR3&#xD;
      SNP rs139130389 and the outcome of TKI discontinuation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We aim to detect FOLR3 SNP rs139130389, and establish its correlation with patients'&#xD;
      treatment response, remission time, TKI resistance and the outcome of TKI stopping.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>treatment-free remission or relapse</measure>
    <time_frame>1 year</time_frame>
    <description>Observe whether the patients were in remission or relapse 1 year after drug withdrawal</description>
  </primary_outcome>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Folate</condition>
  <condition>CML</condition>
  <condition>Treatment-free Remission</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      5ml Peripheral blood of CML patients who discontinued TKI treatment are extracted and stored.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1. The patient signs the informed consent form&#xD;
&#xD;
          2. Age over 18, male or female&#xD;
&#xD;
          3. The patient was diagnosed as chronic phase of CML.&#xD;
&#xD;
          4. ECoG score 0-2&#xD;
&#xD;
          5. Receive TKI treatment for at least 4 years and continuously obtain MR4 or mr4.5 for at&#xD;
             least 3 years.&#xD;
&#xD;
          6. The subjects fully understand and comply with the requirements of the research scheme&#xD;
             and are willing to complete the research as planned.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient signs the informed consent form&#xD;
&#xD;
          2. Age over 18, male or female&#xD;
&#xD;
          3. The patient was diagnosed as chronic phase of CML.&#xD;
&#xD;
          4. ECoG score 0-2&#xD;
&#xD;
          5. Receive TKI treatment for at least 4 years and continuously obtain MR4 or mr4.5 for at&#xD;
             least 3 years.&#xD;
&#xD;
          6. The subjects fully understand and comply with the requirements of the research scheme&#xD;
             and are willing to complete the research as planned.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        NA&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Hong Liu, Doctorate</last_name>
    <role>Study Chair</role>
    <affiliation>Affiliated Hospital of Nantong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hong Liu, Doctorate</last_name>
    <phone>+8613951300660</phone>
    <email>hongliu63@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lu Zhou, Doctorate</last_name>
    <phone>18761720268</phone>
    <email>xueyezhoulu2007@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Affliated Hospital of Nantong University</name>
      <address>
        <city>Nantong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong N Liu, Doctorate</last_name>
      <phone>+8613951300660</phone>
      <email>hongliu63@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Lu Zhou, Doctorate</last_name>
      <phone>18761720268</phone>
      <email>xueyezhoulu2007@sina.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 29, 2021</study_first_submitted>
  <study_first_submitted_qc>November 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2021</study_first_posted>
  <last_update_submitted>November 29, 2021</last_update_submitted>
  <last_update_submitted_qc>November 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FOLR3</keyword>
  <keyword>CML</keyword>
  <keyword>TFR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

